News
HOOK
1.180
0.00%
0.000
Weekly Report: what happened at HOOK last week (0427-0501)?
Weekly Report · 6d ago
Weekly Report: what happened at HOOK last week (0420-0424)?
Weekly Report · 04/27 10:13
Weekly Report: what happened at HOOK last week (0413-0417)?
Weekly Report · 04/20 10:09
Weekly Report: what happened at HOOK last week (0406-0410)?
Weekly Report · 04/13 10:13
Weekly Report: what happened at HOOK last week (0330-0403)?
Weekly Report · 04/06 10:13
Weekly Report: what happened at HOOK last week (0323-0327)?
Weekly Report · 03/30 10:13
Weekly Report: what happened at HOOK last week (0316-0320)?
Weekly Report · 03/23 10:10
Weekly Report: what happened at HOOK last week (0309-0313)?
Weekly Report · 03/16 10:09
Weekly Report: what happened at HOOK last week (0302-0306)?
Weekly Report · 03/09 10:10
Weekly Report: what happened at HOOK last week (0223-0227)?
Weekly Report · 03/02 10:09
Weekly Report: what happened at HOOK last week (0216-0220)?
Weekly Report · 02/23 10:09
Weekly Report: what happened at HOOK last week (0209-0213)?
Weekly Report · 02/16 10:09
Weekly Report: what happened at HOOK last week (0202-0206)?
Weekly Report · 02/09 10:10
HOOKIPA Pharma T0 Sell Oncology Assets HB-200 And HB-700 To NeoTrail Therapeutics
NASDAQ · 02/04 08:57
HOOKIPA Pharma to sell oncology assets to NeoTrail Therapeutics
Seeking Alpha · 02/03 14:26
Weekly Report: what happened at HOOK last week (0126-0130)?
Weekly Report · 02/02 10:10
Weekly Report: what happened at HOOK last week (0119-0123)?
Weekly Report · 01/26 10:10
Weekly Report: what happened at HOOK last week (0112-0116)?
Weekly Report · 01/19 10:15
Weekly Report: what happened at HOOK last week (0105-0109)?
Weekly Report · 01/12 10:14
Weekly Report: what happened at HOOK last week (1229-0102)?
Weekly Report · 01/05 10:09
More
Webull provides a variety of real-time HOOK stock news. You can receive the latest news about Hookipa Pharma through multiple platforms. This information may help you make smarter investment decisions.
About HOOK
HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company developing a new class of immunotherapeutics based on its proprietary arenavirus platform that is designed to target and amplify T cell and immune responses to fight diseases. The Company's replicating and non-replicating technologies are engineered to induce robust and durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. The Company is also engaged in the assessment of strategic alternatives and the development of infectious disease therapies in partnership with other companies. Its Hepatitis B (HBV) program, HB-400, and its Human Immunodeficiency Virus (HIV) program, HB-500, are developed in a partnership with Gilead Sciences Inc.